Lake Street lowered the firm’s price target on Evaxion Biotech (EVAX) to $6 from $35 and keeps a Buy rating on the shares after the company closed a 4M ADS offering at $2.71 and also issued 2M warrants at $2.71. Management expects net proceeds from the offering will extend the cash runway into mid-2026, beyond the anticipated Merck (MRK) milestone payments, the analyst noted. Given that Merck participated in the fundraising, “it stands to reason investors should feel more confident about the possibility of Merck pulling the trigger on either or both EVX-B2 and EVX-B3,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech Closes $10.8 Million Public Offering to Boost Vaccine Development
- Evaxion Biotech Announces $10.8 Million Public Offering to Advance Vaccine Development
- Evaxion Biotech prices 3.997M ADSs at $2.71 in public ofering
- Evaxion Secures Nasdaq Compliance Extension Amid Equity Restoration
- Evaxion Biotech granted 180-day compliance extension by Nasdaq
Questions or Comments about the article? Write to editor@tipranks.com